Isobaric labeling and tandem mass spectrometry: A novel approach for profiling and quantifying proteins differentially expressed in amniotic fluid in preterm labor with and without intra-amniotic infection/inflammation

Romero, Roberto; Kusanovic, Juan Pedro; Gotsch, Francesca; Erez, Offer; Vaisbuch, Edi; Mazaki‐Tovi, Shali; Moser, Allan; Tam, Sunny Wing-Yee; Leszyk, John D.; Master, Stephen R.; Juhász, Péter; Pacora, Percy; Oggè, Giovanna; Gomez, R. Vazquez; Yoon, Bo Hyun; Yeo, Lami; Hassan, Sonia S.; Rogers, Wade T.

doi:10.1080/14767050903067386

Cited by 19 publications

(34 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…104,105 In recent years, proteomics has been extensively used to search for biologically relevant biomarkers and to generate protein profiles characteristic of intraamniotic infection/inflammation and preterm birth. [106][107][108] Nevertheless, up to now, only one study has evaluated proteomics as a potential biomarker to predict spontaneous preterm birth. Shah et al 92 randomly selected samples of cervicovaginal fluid collected at 24-28 weeks of gestation from five women who delivered preterm between 28 and 32 weeks of gestation following spontaneous preterm labour, and five women who delivered after 37 weeks of gestation.…”

Section: Discussionmentioning

confidence: 99%

Novel biomarkers for the prediction of the spontaneous preterm birth phenotype: a systematic review and meta-analysis

Conde-Agudelo

Papageorghiou

Kennedy

et al. 2011

BJOG: An International Journal of Obstetrics &Amp; Gynaecology

147

114

View full text Add to dashboard Cite

Background Being able to predict preterm birth is important, as it may allow a high-risk population to be selected for future interventional studies and help in understanding the pathways that lead to preterm birth.Objective To investigate the accuracy of novel biomarkers to predict spontaneous preterm birth in women with singleton pregnancies and no symptoms of preterm labour.Search strategy Electronic searches in PubMed, Embase, Cinahl, Lilacs, and Medion, references of retrieved articles, and conference proceedings. No language restrictions were applied.Selection criteria Observational studies that evaluated the accuracy of biomarkers proposed in the last decade to predict spontaneous preterm birth in asymptomatic women. We excluded studies in which biomarkers were evaluated in women with preterm labour.Data collection and analysis Two reviewers independently extracted data on study characteristics, quality, and accuracy. Data were arranged in 2 · 2 contingency tables and synthesised separately for spontaneous preterm birth before 32, 34, and 37 weeks of gestation. We used bivariate meta-analysis to estimate pooled sensitivities and specificities, and calculated likelihood ratios (LRs).Main results A total of 72 studies, including 89 786 women and evaluating 30 novel biomarkers, met the inclusion criteria. Only three biomarkers (proteome profile and prolactin in cervicovaginal fluid, and matrix metalloproteinase-8 in amniotic fluid) had positive LRs > 10. However, each of these biomarkers was evaluated in only one small study. Four biomarkers had a moderate predictive accuracy (interleukin-6 and angiogenin, in amniotic fluid; human chorionic gonadotrophin and phosphorylated insulin-like growth factor binding protein-1, in cervicovaginal fluid). The remaining biomarkers had low predictive accuracies.Conclusions None of the biomarkers evaluated in this review meet the criteria to be considered a clinically useful test to predict spontaneous preterm birth. Further large, prospective cohort studies are needed to evaluate promising biomarkers such as a proteome profile in cervicovaginal fluid.

show abstract

Section: Discussionmentioning

confidence: 99%

Novel biomarkers for the prediction of the spontaneous preterm birth phenotype: a systematic review and meta-analysis

Conde-Agudelo

Papageorghiou

Kennedy

et al. 2011

BJOG: An International Journal of Obstetrics &Amp; Gynaecology

147

114

View full text Add to dashboard Cite

show abstract

“…The main finding of this study was that OGN was a predictor of clinical outcomes including all-cause mortality and composite outcome in nondiabetic patients with CKD, but not in diabetic patients with CKD. OGN is a bone-associated glycoprotein (Bentz et al 1990) and has been involved in a variety of biological processes such as bone formation (Bentz et al 1990), cochlear development (Williamson et al 2008), preterm labor (Romero et al 2010), and tumor biology (Hu et al 2005). OGN belongs to the family of small leucine-rich proteoglycans and is a basic component of the vascular extracellular matrix (Shanahan et al 1997;Iozzo 1999;Cheng et al 2014;Van Aelst et al 2015).…”

Section: Discussionmentioning

confidence: 99%

Higher Serum Levels of Osteoglycin Are Associated with All-Cause Mortality and Cardiovascular and Cerebrovascular Events in Patients with Advanced Chronic Kidney Disease

Baek

Hui

Kang

et al. 2017

Tohoku J. Exp. Med.

View full text Add to dashboard Cite

Patients with chronic kidney disease (CKD) have markedly increased rates of major adverse cardiovascular and cerebrovascular events (MACCEs) and mortality. Therefore, identifying early biomarkers predicting clinical outcomes in patients with CKD is critical. We aimed to determine whether osteoglycin, a basic component of the vascular extracellular matrix, was associated with MACCEs or all-cause mortality, using data from a prospective randomized controlled study, K-STAR (Kremezin STudy Against Renal disease progression in Korea: NCT 00860431). A total of 383 patients (mean age: 56.4 years, men/women = 252/131) with CKD stage 3 to 4 from the original trial were enrolled in the present study. We measured serum osteoglycin level and examined the impact of osteoglycin on clinical outcomes. The mean value of osteoglycin levels was 13.3 ± 9.4 ng/mL (healthy control: 5.3 ± 2.1 ng/mL). In multivariable analysis, lower levels of proteinuria and hemoglobin and higher levels of C-reactive protein were significantly associated with higher osteoglycin levels. Estimated glomerular filtration rate was not related to osteoglycin level. During a mean follow-up period of 56 months, 25 deaths, 61 MACCEs, and 76 composite outcomes (all-cause mortality or MACCEs) occurred. In the non-diabetic group, each 1-ng/mL increase in serum osteoglycin was associated with all-cause mortality and composite outcome (hazard ratio [HR] = 1.058, P = 0.031; HR = 1.041, P = 0.036). However, osteoglycin levels were not associated with mortality, MACCEs, or composite outcome in the diabetic group. Our results indicate that serum osteoglycin is a potential predictor of adverse outcomes in patients with CKD.

show abstract

“…Osteoglycin has been implicated in a variety of biological processes such as bone formation, 7 cochlear development, 8 preterm labor, 9 tumor biology, 10 corneal transparency, 11 and skin integrity. 12 Recently, it was identified as a marker of cardiac hypertrophy in genome-wide analysis of the human heart.…”

mentioning

confidence: 99%

Osteoglycin Prevents Cardiac Dilatation and Dysfunction After Myocardial Infarction Through Infarct Collagen Strengthening

Aelst

Voss

Carai

et al. 2015

Circulation Research

View full text Add to dashboard Cite

I schemic heart disease is the leading cause of death in Europe and the US 1 and represents a huge socioeconomic burden. With improved treatment strategies, patient mortality is decreasing, yet acute post-infarct-related heart failure (HF) because of infarct expansion remains a major problem, 2 lacking targeted molecular therapy. Therefore, better understanding of the infarct healing process and the consequent remodeling may result in new treatment options.The tissue repair process after an ischemic event begins with an inflammatory phase, where innate and adaptive immune Rationale: To maintain cardiac mechanical and structural integrity after an ischemic insult, profound alterations occur within the extracellular matrix. Osteoglycin is a small leucine-rich proteoglycan previously described as a marker of cardiac hypertrophy.Objective: To establish whether osteoglycin may play a role in cardiac integrity and function after myocardial infarction (MI). Methods and Results:Osteoglycin expression is associated with collagen deposition and scar formation in mouse and human MI. Absence of osteoglycin in mice resulted in significantly increased rupture-related mortality with tissue disruption, intramyocardial bleeding, and increased cardiac dysfunction, despite equal infarct sizes. Surviving osteoglycin null mice had greater infarct expansion in comparison with wild-type mice because of impaired collagen fibrillogenesis and maturation in the infarcts as revealed by electron microscopy and collagen polarization. Absence of osteoglycin did not affect cardiomyocyte hypertrophy in the remodeling remote myocardium. In cultured fibroblasts, osteoglycin knockdown or supplementation did not alter transforming growth factor-β signaling. Adenoviral overexpression of osteoglycin in wild-type mice significantly improved collagen quality, thereby blunting cardiac dilatation and dysfunction after MI. In osteoglycin null mice, adenoviral overexpression of osteoglycin was unable to prevent rupture-related mortality because of insufficiently restoring osteoglycin protein levels in the heart. Finally, circulating osteoglycin levels in patients with heart failure were significantly increased in the patients with a previous history of MI compared with those with nonischemic heart failure and correlated with survival, left ventricular volumes, and other markers of fibrosis. Conclusions:Increased osteoglycin expression in the infarct scar promotes proper collagen maturation and protects against cardiac disruption and adverse remodeling after MI. In human heart failure, osteoglycin is a promising biomarker for ischemic heart failure. (Circ Res. 2015;116:425-436.

show abstract

Isobaric labeling and tandem mass spectrometry: A novel approach for profiling and quantifying proteins differentially expressed in amniotic fluid in preterm labor with and without intra-amniotic infection/inflammation

Cited by 19 publications

References 0 publications

Novel biomarkers for the prediction of the spontaneous preterm birth phenotype: a systematic review and meta-analysis

Novel biomarkers for the prediction of the spontaneous preterm birth phenotype: a systematic review and meta-analysis

Higher Serum Levels of Osteoglycin Are Associated with All-Cause Mortality and Cardiovascular and Cerebrovascular Events in Patients with Advanced Chronic Kidney Disease

Osteoglycin Prevents Cardiac Dilatation and Dysfunction After Myocardial Infarction Through Infarct Collagen Strengthening

Contact Info

Product

Resources

About